Slide 1: Anteo Shareholder Presentation
ANTEO SHAREHOLDER PRESENTATION ASX Release 7 August 2018 Anteo Diagnostics Ltd (“Company”) is pleased to provide the attached shareholder presentation that will be presented to shareholders in Brisbane, Sydney and Melbourne over the next three days. The Shareholder briefings will update shareholders
Slide 2: Investor Update
Investor Update August 2018 Dr Jack Hamilton (Chair) Mr Christopher Parker (CEO)
Slide 3: Disclaimer
Disclaimer The purpose of the presentation is to provide an update of the business of Anteo Diagnostics Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the i
Slide 4: Agenda
Agenda • Anteo’s Strategy and Focus Areas • Batteries • Point of Care • Summary
Slide 5: Anteo's Strategy & Focus Areas
Anteo’s Strategy & Focus Areas
Slide 6: Strategy & Focus Areas
Strategy & Focus Areas The Board has re-visited the purpose and strategy outlined last November and 1 has narrowed the focus of exploiting the company’s IP to the potential AnteoCoatTM offers in the battery market and to the superior conjugation properties of AnteoBindTM in the Point of Care market.
Slide 7: Anteo's markets, opportunities, and focus areas
Anteo’s markets, opportunities, and focus areas ANTEO FOCUS AREAS In Vitro & Life Energy Point of Care MedTech Science Diagnostics – AnteoCoat - AnteoBind - AnteoRelease - AnteoBind $6bn market >$2.5bn market $2bn market >$30bn market Si Anodes Orthopedic Infectious diseases Academia implants Cathod
Slide 8: Funnel of Opportunities
Funnel of Opportunities • Focus is on driving the near term MEDTECH CARDIOLOGY opportunities to commercial DRUG BATTERY ANODE realisation where demonstrable ELUTING ENHANCEMENT STENTS benefit is available to users SILICON/ BATTERY ANODE GRAPHITE ENHANCEMENT COMPOSITES SILICON/ • Battery focus is on
Slide 9: Batteries
Batteries Se anteo diagnostics
Slide 10: Why is Anteo pursuing Battery Opportunities?
Why is Anteo pursuing Battery Opportunities? • The world is on a path to electrification. Batteries will play an ever LI-ION CELLS $M, Worldwide, 2000 - 2025 increasing role in transport as well as many industrial and home 80,000.00 uses, such as energy storage, tools etc. 70,000.00 • Market growth.
Slide 11: Why silicon?
Why silicon? THE OPPORTUNITY THE CHALLENGE • Higher silicon content in battery anodes equates to • When the battery is charged (lithium ions migrating from higher electrical storage capacity compared to cathode to anode) silicon swells up to 300% of its size conventional graphite and a resulting low
Slide 12: Work with AnteoCoat has given encouraging results towards being part of the solution
Work with AnteoCoat™ has given encouraging results towards being part of the solution.
Slide 13: Problem and Current Solution
Problem and Current Solution GRAPHITE ACTIVE MATERIAL PROBLEM: - Limited capacity but - Stable and safe performance Energy density is nearing its limit HIGH ENERGY ACTIVE MATERIALS CATHODE - Micro-silicon has high energy but poor stability - Nano-silicon is hard to integrate into electrode - Added i
Slide 14: Technology Development Two Focus Areas
Technology Development Two Focus Areas INCREASE OF BATTERY ENERGY DENSITY: • Increase in silicon content in lithium ion battery anodes to increase anode capacity and cell energy density • Two approaches are being investigated • 1) Surface coatings on silicon particles enabled by AnteoCoat™ • 2) The
Slide 15: AnteoCoat and Silicon in Batteries
AnteoCoat™ and Silicon in Batteries Silicon particle coatings enabled by AnteoCoat™ are targeting: • Up to 20wt.% Si content in anode • Surface coating applied to silicon particles achieves • Improved material processing • Performance improving coating Silicon/carbon composite particle coatings enab
Slide 16: AnteoCoat – Processing Achievements
AnteoCoat™ – Processing Achievements • Internal development work has been heavily focused on demonstrating the use of AnteoCoat™ in lab-scale processes that allow for the creation of: • 1) Silicon particle coatings • 2) Silicon/carbon composites nano-Si/C composite • Anteo has demonstrated that both
Slide 17: Particle Coating Results Encouraging
Particle Coating Results Encouraging The commissioned work by Polaris on the evaluation of Anteo’s coated silicon particles demonstrated that: • 1) For a 10wt.% silicon anode a better starting capacity, compared to a 10wt.% silicon anode without AnteoCoat, could be achieved Polaris: “AnteoCoat™ impr
Slide 18: Silicon Particle Coating – CustomCells
Silicon Particle Coating – CustomCells • Anteo’s coated silicon particles were processed into anode electrodes and paired with commercial cathode electrodes (NCM 622) by CustomCells • Tests were conducted with full pouch cells using a Nokia type cell format • Full cells were created successfully and
Slide 19: Composite Particle Results Encouraging
Composite Particle Results Encouraging • The commissioned work by Polaris showed Anteo’s silicon/carbon composite was able to produce a working battery using an anode with a silicon content of 24wt.% demonstrating a substantial improvement in electrode capacity compared to a conventional graphite an
Slide 20: AnteoCoat Potential in Battery Manufacturing
AnteoCoat™ Potential in Battery Manufacturing • The second development stream is evaluating the potential for AnteoCoat™ to improve electrode performance and generate cost reductions by increasing electrode and battery processing efficiencies • Processing efficiencies can be introduced through surfa
Slide 21: Battery Separator - Wettability Studies
Battery Separator - Wettability Studies • Surface modified carbon enabled by AnteoCoat™ demonstrated improved wetting and dispersion in water • One target is to increase processing efficiencies during component mixing and electrode coating steps Carbon particle agglomeration in Surface modified carb
Slide 22: Established Battery Team & Internal Battery Lab
Established Battery Team & Internal Battery Lab Materials science and energy storage technologies. MANUEL WIESER HEAD OF BATTERY DEVELOPMENT Technology management and collaboration experience in Australia, US and Europe. 30 years experience in chemical engineering, production scale-up and process op
Slide 23: Internal Battery Capabilities
Internal Battery Capabilities • Internal battery capabilities allow Anteo to mix battery anode slurries, cast slurries onto current collector foils and assemble electrodes into coin cells for electrochemical evaluation • Internal battery capabilities will allow for improved control of testing parame
Slide 24: Battery next steps
Battery next steps 1 Tested interest and relevance of AnteoCoat™ preliminary results at various trade conferences – Complete. Verified interest. Follow up discussions identifying potential commercial partners to seek involvement in next 2 stages with focus being on: - Progressing the near term devel
Slide 25: Point of Care
Point of Care Se anteo diagnostics
Slide 26: Tested Shift in PoC Market and Role for AnteoBind
Tested Shift in PoC Market and Role for AnteoBind™ LFIA market Confirmation of AnteoBind™ opportunities in quantitative lateral flow USD $Billions assays at Lateral Flow conference (Spain) in May: • The Lateral Flow Immunoassay (LFIA) segment continues to grow strongly within the overall Point-Of-Ca
Slide 27: Point Of Care and Life Sciences Commercial Focus
Point Of Care and Life Sciences Commercial Focus • AnteoBind™ is making a clear difference solving customer issues in relation to antibody conjugation. Critical when building quantitative LFIA systems using the following detection systems: • Europium, Gold, Quantum Dots (e.g. Ellume), Dyes and poten
Slide 28: AnteoBind FluB Europium Conjugates
AnteoBind™ FluB Europium Conjugates Improving Batch Reproducibility & Performance 300.0 Batch 1 Batch 2 Batch 3 Average 250.0 Rela ve Fluoresence Unit 200.0 150.0 100.0 50.0 0.0 0 1/5000 1/1000 1/500 FluB Ab Fluoro-Max par cles ANTEOBIND™ Your ENABLES title EXCELLENT INTRA & INTER BATCH REPRODUCIBIL
Slide 29: AnteoBind cTnI Europium Conjugates
AnteoBind™ cTnI Europium Conjugates Improving Batch Reproducibility & Performance 2000.0 0 pg/mL 100 pg/mL 1000 pg/mL 2000 pg/mL 1400.0 1800.0 Batch 1 Batch 2 Batch 3 1600.0 1200.0 Fluoresence Unit (mV) Linear (Batch 1) Linear (Batch 2) Linear (Batch 3) 1400.0 Fluorescence Unit (mV) 1000.0 1200.0 80
Slide 30: AnteoBind Compatibility Europium Particles from Suppliers: hCG Assay
AnteoBind™ Compatability Europium Particles from 3 Suppliers: hCG Assay ANTEOBIND™Your FUNCTIONAL title COATING IS COMPATIBLE WITH THREE COMMERCIALLY AVAILABLE Your title EUROPIUM PARTICLES AND SHOWED SIMILAR HCG & CTNI (DATA NOT SHOWN) LOD
Slide 31: AnteoBind Value: Simplifying Multiplex LFIA
AnteoBind™ Value: Simplifying Multiplex LFIA - Europium FluA/FluB LFIA ANTEOBIND™ FUNCTIONAL COATING DELIVERS SENSITIVE EUROPIUM FLUA/FLUB DUAL-PLEX LATERAL FLOW IMMUNOASSAY Your title Your title
Slide 32: AnteoBind - What the results tell us
AnteoBind™ - What the results tell us • Significant gains in limit of detection performance across all tests • Improved reproducibility of conjugate manufacturing • Simple method and stable in storage • Improved assay performance • Better analytical sensitivity & lower limit of detection • Quicker t
Slide 33: Anteo POC Business Model Focus
Anteo POC Business Model Focus Research large IVD Assay or Reader POCT LFIA companies Particle companies Anteo own brand LFIA POCT VALUE CHAIN companies companies Develop full POCT assays High value, High value, High value, - ISO13485 high competition high competition high competition High value Con
Slide 34: Anteo POC Business Model Focus
Anteo POC Business Model Focus Research large IVD Assay or Reader POCT LFIA companies Particle companies Anteo own brand LFIA POCT VALUE CHAIN companies companies Develop full POCT assays High value, High value, High value, - ISO13485 high competition high competition high competition High value Con
Slide 35: Anteo POC Business Model Focus
Anteo POC Business Model Focus Research large IVD Assay or Reader POCT LFIA companies Particle companies Anteo own brand LFIA POCT VALUE CHAIN companies companies Develop full POCT assays High value, High value, High value, - ISO13485 high competition high competition high competition High value Con
Slide 36: Anteo POC Business Model Focus
Anteo POC Business Model Focus Research large IVD Assay or Reader POCT LFIA companies Particle companies Anteo own brand LFIA POCT VALUE CHAIN companies companies Develop full POCT assays High value, High value, High value, - ISO13485 high competition high competition high competition High value Con
Slide 37: Point of Care next steps
Point of Care next steps Offer conjugation services starting with a “suite” of activated 1 particle kits (plus validation data package) - reopen/revitalise large geographic market opportunities ie China/Japan with this approach - test approach with current customers and Lateral Flow PoC companies at
Slide 38: Summary
Summary Se anteo diagnostics
Slide 39: Anteo Focus in Summary
Anteo Focus in Summary BATTERY PARTNERSHIPS ANTEOBIND MESSAGING Develop external Battery partnerships Re-focus AnteoBind™ messaging on through Q3 based on the results obtained superior conjugation performance and solving difficult assay development with COMMERCIAL DEVELOPMENT Europium, Gold, Quantum
Slide 40: For more information contact
For more information contact Mr Christopher Parker CEO chris.parker@anteodx.com Dr Jack Hamilton Chair jack.hamilton@anteodx.com Mr Julien McInally Company Sec. julien.mcinally@anteodx.com anteotech.com ASX:ADO